[go: up one dir, main page]

MX2018010436A - Composicion farmaceutica disuasiva del abuso. - Google Patents

Composicion farmaceutica disuasiva del abuso.

Info

Publication number
MX2018010436A
MX2018010436A MX2018010436A MX2018010436A MX2018010436A MX 2018010436 A MX2018010436 A MX 2018010436A MX 2018010436 A MX2018010436 A MX 2018010436A MX 2018010436 A MX2018010436 A MX 2018010436A MX 2018010436 A MX2018010436 A MX 2018010436A
Authority
MX
Mexico
Prior art keywords
enzyme
drug
pharmaceutical composition
abuse
functional group
Prior art date
Application number
MX2018010436A
Other languages
English (en)
Inventor
Greimel Katrin
Brandauer Martin
Huber Daniela
Bleymaier Klaus
Kroutil Wolfgang
Lechner Doris
Wachter Christof
Wagner Harald
Winkler Heimo
Gübitz Georg
Original Assignee
G L Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by G L Pharma Gmbh filed Critical G L Pharma Gmbh
Publication of MX2018010436A publication Critical patent/MX2018010436A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/13—Transferases (2.) transferring sulfur containing groups (2.8)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Se describe una composición farmacéutica disuasiva del abuso que comprende un fármaco con un grupo funcional reactivo con enzima, en donde el fármaco tiene un potencial de abuso y una enzima capaz de reaccionar con el grupo funcional reactivo a la enzima (enzima de procesamiento del fármaco), en donde el fármaco con el grupo funcional reactivo a la enzima está contenido en la composición farmacéutica en un estado reactivo con la enzima, estable al almacenamiento y en condiciones en donde ninguna actividad enzimática actúa sobre la droga.
MX2018010436A 2016-02-29 2017-02-28 Composicion farmaceutica disuasiva del abuso. MX2018010436A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16157798.6A EP3210596A1 (en) 2016-02-29 2016-02-29 Abuse-deterrent pharmaceutical composition
PCT/EP2017/054614 WO2017148927A1 (en) 2016-02-29 2017-02-28 Abuse-deterrent pharmaceutical composition

Publications (1)

Publication Number Publication Date
MX2018010436A true MX2018010436A (es) 2019-05-22

Family

ID=55446691

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018010436A MX2018010436A (es) 2016-02-29 2017-02-28 Composicion farmaceutica disuasiva del abuso.

Country Status (11)

Country Link
US (1) US11077196B2 (es)
EP (3) EP3210596A1 (es)
JP (1) JP2019507173A (es)
CN (1) CN109069419A (es)
AU (1) AU2017226880A1 (es)
BR (1) BR112018067613A2 (es)
CA (1) CA3016578A1 (es)
CL (1) CL2018002463A1 (es)
ES (1) ES2745579T3 (es)
MX (1) MX2018010436A (es)
WO (1) WO2017148927A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3231420A1 (en) * 2016-02-29 2017-10-18 G.L. Pharma GmbH Abuse-deterrent pharmaceutical compositions
CN111269901B (zh) * 2020-02-18 2021-08-24 浙江科技学院 一种环氧化物水解酶突变体及其应用
WO2023225630A2 (en) * 2022-05-19 2023-11-23 Virginia Commonwealth University FORMULATIONS FOR ADMINISTERING LAAM, norLAAM AND dinorLAAM AND METHODS OF THEIR USE TO TREAT OPIOID USE DISORDER

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3852157A (en) * 1971-05-14 1974-12-03 Syva Corp Compounds for enzyme amplification assay
US4391904A (en) * 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4299916A (en) 1979-12-26 1981-11-10 Syva Company Preferential signal production on a surface in immunoassays
JPH02238885A (ja) 1989-03-13 1990-09-21 Oji Paper Co Ltd フェノールオキシダーゼ遺伝子組換えｄｎａ、該組換えｄｎａにより形質転換された微生物、その培養物及びフェノールオキシダーゼの製造方法
FI903443A7 (fi) 1990-07-06 1992-01-07 Valtion Teknillinen Framstaellning av lackas genom rekombinantorganismer.
ES2148168T3 (es) 1991-03-22 2000-10-16 Novo Nordisk As Proceso para la produccion de proteinas peroxidasas de una cepa de aspergillus.
DK77393D0 (da) 1993-06-29 1993-06-29 Novo Nordisk As Aktivering af enzymer
AU3517695A (en) 1994-09-27 1996-04-19 Novo Nordisk A/S Enhancers such as acetosyringone
AU1721697A (en) 1996-01-31 1997-08-22 Gist-Brocades B.V. Use of compositions comprising stabilized biologically effective compounds
WO1997041215A1 (en) 1996-04-29 1997-11-06 Novo Nordisk A/S Non-aqueous, liquid, enzyme-containing compositions
JP3320307B2 (ja) 1996-06-06 2002-09-03 株式会社エス・ディー・エス バイオテック フェノール性化合物等の高分子化方法及びその利用
GB9622516D0 (en) * 1996-10-29 1997-01-08 Univ Cambridge Tech Enzymic cofactor cycling
ATE225612T1 (de) 1998-07-08 2002-10-15 Novozymes As Verwendung eines phenoloxidierenden enzymes zum behandeln von tabak
CA2349490C (en) 1998-11-09 2011-06-14 Novozymes A/S Antimicrobial composition comprising an oxidoreductase and an enhancing agent of the n-hydroxyanilide-type
DE10029671A1 (de) 2000-06-23 2002-01-10 Frieder Schauer Biotransformation von biologisch aktiven Verindungen aus verschiedenen chemischen Stoffklassen mittels der Enzyme Laccase und Manganperoxidase
WO2003013433A2 (en) 2001-08-06 2003-02-20 Euro-Celtique S.A. Sequestered antagonist formulations
US7169752B2 (en) * 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
WO2004026283A1 (en) 2002-09-20 2004-04-01 Alpharma, Inc. Sequestering subunit and related compositions and metohds
AU2003287935B2 (en) 2003-12-30 2008-02-28 Gumlink A/S Chewing gum comprising biodegradable polymers and having accelerated degradability
AU2012201450A1 (en) * 2004-11-24 2012-04-05 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20060177380A1 (en) 2004-11-24 2006-08-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
WO2006133733A1 (en) * 2005-06-13 2006-12-21 Flamel Technologies Oral dosage form comprising an antimisuse system
AU2006344611A1 (en) 2006-06-16 2007-12-21 Gumlink A/S Chewing gum comprising a hydrophobic enzyme formulation
KR20140079441A (ko) 2006-06-19 2014-06-26 알파마 파머슈티컬스 엘엘씨 약제학적 조성물
CA2671197A1 (en) 2006-07-21 2008-01-24 Lab International Srl Hydrophobic abuse deterrent delivery system
DE102006048833A1 (de) 2006-10-16 2008-04-17 Universität Rostock Behandlung von Osteoporose
JP5484062B2 (ja) * 2006-12-04 2014-05-07 オレクソ・アクチエボラゲット オピオイドを含む新規の非−乱用性医薬組成物
ES2660674T3 (es) * 2009-03-04 2018-03-23 Emplicure Ab Formulación resistente al abuso
US20110262359A1 (en) * 2010-04-21 2011-10-27 Jenkins Thomas E Compositions comprising enzyme-cleavable prodrugs of active agents and inhibitors thereof
MX382405B (es) 2010-07-02 2025-03-13 Procter & Gamble Método para suministrar un agente activo.
EP2635258A1 (en) 2010-11-04 2013-09-11 AbbVie Inc. Drug formulations
EP2655527A1 (de) 2010-12-20 2013-10-30 ALLNEX AUSTRIA GmbH Verfahren zur härtung von oberflächenbeschichtungsmitteln
US8497237B2 (en) * 2011-01-11 2013-07-30 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable oxycodone prodrug
JP2014505736A (ja) 2011-02-17 2014-03-06 キューアールエックスファーマ リミテッド 固体投薬形態の乱用を防止するための技術
CA2827662C (en) 2011-03-09 2020-07-14 Signature Therapeutics, Inc. Active agent prodrugs with heterocyclic linkers
WO2013063204A1 (en) 2011-10-26 2013-05-02 Kempharm, Inc. Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydromorphone, prodrugs, methods of making and use thereof
MX392839B (es) 2012-11-30 2025-03-24 Acura Pharmaceuticals Inc Liberacion autorregulada de ingrediente farmaceutico activo.
JP6198495B2 (ja) 2013-07-12 2017-09-20 キヤノン株式会社 画像形成装置
AU2014306759B2 (en) 2013-08-12 2018-04-26 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
EP3231420A1 (en) 2016-02-29 2017-10-18 G.L. Pharma GmbH Abuse-deterrent pharmaceutical compositions
EP3210630A1 (en) 2016-02-29 2017-08-30 G.L. Pharma GmbH Abuse-deterrent pharmaceutical compositions

Also Published As

Publication number Publication date
JP2019507173A (ja) 2019-03-14
EP3210596A1 (en) 2017-08-30
BR112018067613A2 (pt) 2019-04-09
CL2018002463A1 (es) 2018-10-12
EP3423034B1 (en) 2019-07-10
EP3560484A1 (en) 2019-10-30
US11077196B2 (en) 2021-08-03
CN109069419A (zh) 2018-12-21
AU2017226880A1 (en) 2018-08-23
EP3423034A1 (en) 2019-01-09
CA3016578A1 (en) 2017-09-08
US20190060471A1 (en) 2019-02-28
ES2745579T3 (es) 2020-03-02
WO2017148927A1 (en) 2017-09-08

Similar Documents

Publication Publication Date Title
MX2022010490A (es) Composiciones utiles para enzimas de internalizacion.
USD818983S1 (en) Main body of mobile phone
MX2021000384A (es) Contenedor con ensamblaje de ruedas sin eje.
EP4093863A4 (en) CRISPR-CAS ENZYMES WITH ENHANCED ON-TARGET ACTIVITY
MX2010008359A (es) Variantes de alfa-amilasa ts23 con propiedades alteradas.
MX2018014890A (es) Composiciones de limpieza que comprenden enzimas.
JO3522B1 (ar) تركيب صيدلاني يتألف من كريات حمراء تغلف إنزيم يعتمد على بيريدكسال الفوسفات والعامل المساعد له
MY191210A (en) Novel promoter and uses thereof
JOP20190161A1 (ar) مستشعرات جلوكوز بطيف قريب من الأشعة تحت الحمراء
EP4274326A3 (en) Using a cell as a pathloss or timing reference
MY152163A (en) Lipolytic enzyme variants
MX2017002242A (es) Composicion topica que contiene ranpirnase.
MX2018010436A (es) Composicion farmaceutica disuasiva del abuso.
MX2015010094A (es) Elemento de sujecion con iman y metodo para eliminar el tictac y el traqueteo en un elemento de sujecion con iman.
MX2016015261A (es) Dispersion solida de allisartan isoproxilo y su composicion.
MX2020004058A (es) Inhibidores de d-aminoacido oxidasa y sus usos terapeuticos.
EP4467643A3 (en) Compositions comprising a modified glcnac-1-phosphotransferase and methods of use thereof
MY198644A (en) Enzyme composition
PH12014501307A1 (en) Liquid activation system
MX2018010435A (es) Composiciones farmaceuticas disuasivas del abuso.
MY206033A (en) Enzyme composition
MX2022001772A (es) Formulaciones de isotretinoina y usos y metodos de las mismas.
PH12019500952A1 (en) Enzyme composition for therapeutic management of muscle soreness
EP4043364A3 (en) Liquid vessel and method therewith
WO2020163469A3 (en) METHODS FOR DETECTING METEORIN-β ACTIVITY